Trimeris stock got a boost today when Switzerland became the first European country to approve its new AIDS drug, Fuzeon.

Trimeris (Nasdaq: TRMS) stock was up nearly 2 percent, or 87 cents, to $46.88 in early afternoon trading.

The Swiss government also approved reimbursement for costs of the drug. Fuzeon is expected to be available in June.

Fuzeon won FDA approval in the United States in March.